Compare INBK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | IMUX |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | 355 | 66 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 152.6M |
| IPO Year | N/A | 2013 |
| Metric | INBK | IMUX |
|---|---|---|
| Price | $23.81 | $9.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $23.25 | ★ $36.00 |
| AVG Volume (30 Days) | 50.7K | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $0.51 |
| 52 Week High | $28.51 | $10.91 |
| Indicator | INBK | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 85.13 |
| Support Level | $23.52 | $0.75 |
| Resistance Level | $24.85 | N/A |
| Average True Range (ATR) | 0.94 | 0.46 |
| MACD | -0.08 | 1.01 |
| Stochastic Oscillator | 61.69 | 87.07 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.